Benchmark Financial Wealth Advisors LLC Sells 745 Shares of Bristol-Myers Squibb (NYSE:BMY)

Benchmark Financial Wealth Advisors LLC cut its stake in Bristol-Myers Squibb (NYSE:BMYFree Report) by 4.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,244 shares of the biopharmaceutical company’s stock after selling 745 shares during the quarter. Benchmark Financial Wealth Advisors LLC’s holdings in Bristol-Myers Squibb were worth $782,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. OFI Invest Asset Management purchased a new stake in shares of Bristol-Myers Squibb in the third quarter worth approximately $25,000. True Wealth Design LLC purchased a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at $26,000. Milestone Investment Advisors LLC bought a new position in shares of Bristol-Myers Squibb in the third quarter worth about $27,000. Coppell Advisory Solutions LLC purchased a new position in Bristol-Myers Squibb in the 2nd quarter worth about $28,000. Finally, Blue Bell Private Wealth Management LLC lifted its holdings in Bristol-Myers Squibb by 61.5% during the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 200 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on BMY shares. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Redburn Atlantic lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their target price for the company from $77.00 to $54.00 in a research report on Tuesday, February 6th. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday. Bank of America downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $68.00 to $60.00 in a report on Wednesday, January 3rd. Finally, StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $61.12.

Get Our Latest Report on Bristol-Myers Squibb

Bristol-Myers Squibb Stock Down 0.5 %

BMY stock traded down $0.24 on Tuesday, hitting $52.75. 10,233,247 shares of the company’s stock were exchanged, compared to its average volume of 16,652,035. The firm has a 50 day moving average price of $51.03 and a two-hundred day moving average price of $52.25. Bristol-Myers Squibb has a 12-month low of $47.58 and a 12-month high of $71.07. The stock has a market cap of $106.91 billion, a P/E ratio of 13.72, a price-to-earnings-growth ratio of 1.64 and a beta of 0.39. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.55 by $0.15. The business had revenue of $11.48 billion for the quarter, compared to analyst estimates of $11.19 billion. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The company’s revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.82 earnings per share. As a group, equities research analysts expect that Bristol-Myers Squibb will post 6.61 EPS for the current fiscal year.

Bristol-Myers Squibb announced that its board has authorized a stock buyback plan on Thursday, December 7th that permits the company to buyback $3.00 billion in outstanding shares. This buyback authorization permits the biopharmaceutical company to reacquire up to 2.9% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its shares are undervalued.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be paid a dividend of $0.60 per share. The ex-dividend date is Thursday, April 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.55%. Bristol-Myers Squibb’s payout ratio is currently 62.18%.

Bristol-Myers Squibb Company Profile

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Read More

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.